CTCharles L. Paul Thomas

Charles L. Paul Thomas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charles L. Paul Thomas has a total of 179 co-authors. Here are the top co-authors by number of shared publications:

  • Dahlia Salman

    Department of Chemistry, Loughborough University, Loughborough LE11 3TT, UK

    9 shared publications
  • Dorota Ruszkiewicz

    BC Canc Res Inst Vancouver, Integrat Oncol, Vancouver, BC, Canada

    6 shared publications
  • Amisha Singapuri

    Department of Respiratory Sciences, University of Leicester, Leicester, UK

    5 shared publications
  • Kareen Darnley

    Royal Infirmary of Edinburgh, Wellcome Trust Clinical Research Facility, Edinburgh, Edinburgh, EH16 4SA, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND

    5 shared publications
  • Michael Eddleston

    Pharmacology, Toxicology and Therapeutics Unit, University of Edinburgh Division of Clinical and Surgical Sciences, Centre for Cardiovascular Science, Edinburgh, Scotland, EH16 4TJ, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND

    5 shared publications
  • Michael Wilde

    Department of Chemistry, University of Leicester, University Road, Leicester, LE1 7RH, United Kingdom

    4 shared publications

Latest Publications

  • Open Access

    Oscillometry to assess ventilation heterogeneity during hospital admission for acute cardiorespiratory illness

    by Masarrah Aljaroof, Wadah Ibrahim, Hnin Aung, Rebecca L. Cordell, Michael J. Wilde, Matthew Richardson, Dahlia Salman, Amisha Singapuri, Robert C. Free, Erol Gaillard, et al.

    Rationale: Hospitalisation due to exacerbations of cardiorespiratory disease results in reduced lung function and increased airways obstruction. However, traditional measures of lung function require maximal effort which is difficult when patients are unwell ( e.g. FEV 1 ) and may focus on larger airways away from the major part of airways disease ( e.g. peak flow). We aimed to measure whole airways function using oscillometry in patients during hospitalisation with cardiorespiratory illness compared with healthy controls. Method: Participants (n=310) underwent assessment; 263 were admitted to hospital with acute cardiorespiratory illness (asthma (n=80), COPD (n=75), heart failure (n=46) and pneumonia (n=62)) and 47 healthy controls were included. Participants underwent handheld oscillometry measurements within the first 24 h of admission. Results: Oscillometry measurement was feasible in all patients (n=310). There was a significant difference in both absolute and percentage predicted measures of lung mechanics (p<0.05 for all measures), with significantly worse lung mechanics in patients with COPD. Measures of resistance and reactance were worse in those that were more breathless (p<0.0001), had more wheeze (p<0.001) and had low oxygen saturation (p<0.001). No difference was seen based on modified early warning system score or blood biomarkers (eosinophil count, C-reactive protein and brain natriuretic peptide). There were significant improvements in oscillometry measures in those that attended following recovery from acute illness. Conclusion: Handheld oscillometry can be feasibly deployed in the acute care setting to obtain information on respiratory mechanics. It demonstrates significant differences in ventilation heterogeneity between patients in the acute care setting and healthy volunteers.


  • Open Access

    Benchmarking breath analysis using peppermint approach with gas chromatography ion mobility spectrometer coupled to micro thermal desorber

    by Dorota M Ruszkiewicz, Kristian J Kiland, Yoonseo Mok, Crista Bartolomeu, Scott A Borden, Paul Thomas, Stephen Lam, Renelle Myers

    The Peppermint Initiative, established within the International Association of Breath Research, introduced the peppermint protocol, a breath analysis benchmarking effort designed to address the lack of inter-comparability of outcomes across different breath sampling techniques and analytical platforms. Benchmarking with gas chromatography—ion mobility spectrometry (GC-IMS) using peppermint has been previously reported however, coupling micro-thermal desorption (µTD) to GC-IMS has not yet, been benchmarked for breath analysis. To benchmark µTD-GC-IMS for breath analysis using the peppermint protocol. Ten healthy participants (4 males and 6 females, aged 20–73 years), were enrolled to give six breath samples into Nalophan bags via a modified peppermint protocol. Breath sampling after peppermint ingestion occurred over 6 h at t = 60, 120, 200, 280, and 360 min. The breath samples (120 cm3) were pre-concentrated in the µTD before being transferred into the GC-IMS for detection. Data was processed using VOCal, including background subtractions, peak volume measurements, and room air assessment. During peppermint washout, eucalyptol showed the highest change in concentration levels, followed by α-pinene and β-pinene. The reproducibility of the technique for breath analysis was demonstrated by constructing logarithmic washout curves, with the average linearity coefficient of R 2 = 0.99. The time to baseline (benchmark) value for the eucalyptol washout was 1111 min (95% CI: 529–1693 min), obtained by extrapolating the average logarithmic washout curve. The study demonstrated that µTD-GC-IMS is reproducible and suitable technique for breath analysis, with benchmark values for eucalyptol comparable to the gold standard GC-MS.


  • Open Access

    Visualization of exhaled breath metabolites reveals distinct diagnostic signatures for acute cardiorespiratory breathlessness

    by Wadah Ibrahim, Michael J. Wilde, Rebecca L. Cordell, Matthew Richardson, Dahlia Salman, Robert C. Free, Bo Zhao, Amisha Singapuri, Beverley Hargadon, Erol A. Gaillard, et al.

    Acute cardiorespiratory breathlessness accounts for one in eight of all emergency hospitalizations. Early, noninvasive diagnostic testing is a clinical priority that allows rapid triage and treatment. Here, we sought to find and replicate diagnostic breath volatile organic compound (VOC) biomarkers of acute cardiorespiratory disease and understand breath metabolite network enrichment in acute disease, with a view to gaining mechanistic insight of breath biochemical derangements. We collected and analyzed exhaled breath samples from 277 participants presenting acute cardiorespiratory exacerbations and aged-matched healthy volunteers. Topological data analysis phenotypes differentiated acute disease from health and acute cardiorespiratory exacerbation subtypes (acute heart failure, acute asthma, acute chronic obstructive pulmonary disease, and community-acquired pneumonia). A multibiomarker score (101 breath biomarkers) demonstrated good diagnostic sensitivity and specificity (≥80%) in both discovery and replication sets and was associated with all-cause mortality at 2 years. In addition, VOC biomarker scores differentiated metabolic subgroups of cardiorespiratory exacerbation. Louvain clustering of VOCs coupled with metabolite enrichment and similarity assessment revealed highly specific enrichment patterns in all acute disease subgroups, for example, selective enrichment of correlated C5-7 hydrocarbons and C3-5 carbonyls in heart failure and selective depletion of correlated aldehydes in acute asthma. This study identified breath VOCs that differentiate acute cardiorespiratory exacerbations and associated subtypes and metabolic clusters of disease-associated VOCs.


  • Open Access

    Peppermint protocol: first results for gas chromatography-ion mobility spectrometry

    by Dorota M Ruszkiewicz, Renelle Myers, Ben Henderson, Hazim Yusof, Austin Meister, Sergi Moreno, Michael Eddleston, Kareen Darnley, William H Nailon, Duncan McLaren, et al.

    The Peppermint Initiative seeks to inform the standardisation of breath analysis methods. Five Peppermint Experiments with gas chromatography-ion mobility spectrometry (GC-IMS), operating in the positive mode with a tritium 3H 5.68 keV, 370 MBq ionisation source, were undertaken to provide benchmark Peppermint Washout data for this technique, to support its use in breath-testing, analysis, and research. Headspace analysis of a peppermint-oil capsule by GC-IMS with on-column injection (0.5 cm3) identified 12 IMS responsive compounds, of which the four most abundant were: eucalyptol; β-pinene; α-pinene; and limonene. Elevated concentrations of these four compounds were identified in exhaled-breath following ingestion of a peppermint-oil capsule. An unidentified compound attributed as a volatile catabolite of peppermint-oil was also observed. The most intense exhaled peppermint-oil component was eucalyptol, which was selected as a peppermint marker for benchmarking GC-IMS. Twenty-five washout experiments monitored levels of exhaled eucalyptol, by GC-IMS with on-column injection (0.5 cm3), at t = 0 min, and then at t + 60, t + 90, t + 165, t + 285 and t + 360 min from ingestion of a peppermint capsule resulting in 148 peppermint breath analyses. Additionally, the Peppermint Washout data was used to evaluate clinical deployments with a further five washout tests run in clinical settings generating an additional 35 breath samples. Regression analysis yielded an average extrapolated time taken for exhaled eucalyptol levels to return to baseline values to be 429 ± 62 min (±95% confidence-interval). The benchmark value was assigned to the lower 95% confidence-interval, 367 min. Further evaluation of the data indicated that the maximum number of volatile organic compounds discernible from a 0.5 cm3 breath sample was 69, while the use of an in-line biofilter appeared to reduce this to 34.


  • Open Access

    Breath collection protocol for SARS-CoV-2 testing in an ambulatory setting

    by Renelle Myers, Dorota Ruskiewicz, Austin Meister, Atkar Khattra Sukhinder, Crista Bartolomeu, Paul Thomas, Stephen Lam

    Background. The SARS-CoV-2 pandemic changed the way the society functioned. The race to develop a rapid, non-invasive, widely available test resulted in multiple studies examining the potential of breath to be that ‘game changing test’. Breath sampling is a non-invasive point of care test, but SAR-CoV-2 has introduced a level of danger into collection and analysis that requires a change in workflow to keep staff and participants safe. We developed a SARS-CoV 2 breath test work flow for collection and processing of breath samples in an ambulatory care setting and prospectively evaluated the protocol. Protocol development included testing the effect of respiratory filters on the integrity and reproducibility of breath samples. Methods. Prospective, observational study conducted at community COVID-19 testing sites, collecting breath samples from patients presenting for RT-PCR testing. Breath was collected via Tedlar®, and/or BioVOC-2™ as well as an environmental sample for all participants. Samples were transferred to Tenex tubes, dry purged and analyzed using a Centri automated sample introduction machine, GC, and a Bench-ToF-HD. Results. We successfully collected and processed 528 breath samples from 393 participants at community-based ambulatory COVID-19 test sites. The majority of samples were collected before vaccines were available and throughout the emergence of the Delta Variant. No staff member was infected. Conclusion. We demonstrated a safe workflow for the collection, handling, transport, storage, and analysis of breath samples during the pandemic collecting highly infectious SARS-CoV-2 positive breath samples. This was done without filters as they added complexity to the breath matrix, jeopardizing the sample integrity.


  • The utility of a standardised breath sampler in school age children within a real-world prospective study

    by K K Bhavra, M Wilde, M Richardson, R Cordell, P Thomas, B Zhao, L Bryant, C E Brightling, W Ibrahim, D Salman, et al.

    Clinical assessment of children with asthma is problematic, and non-invasive biomarkers are needed urgently. Monitoring exhaled volatile organic compounds (VOCs) is an attractive alternative to invasive tests (blood and sputum) and may be used as frequently as required. Standardised reproducible breath-sampling is essential for exhaled-VOC analysis, and although the ReCIVA (Owlstone Medical Limited) breath-sampler was designed to satisfy this requirement, paediatric use was not in the original design brief. The efficacy of the ReCIVA at sampling breath from children has been studied, and 90 breath-samples from 64 children (5–15 years) with, and without asthma (controls), were collected with two different ReCIVA units. Seventy samples (77.8%) contained the specified 1 l of sampled-breath. Median sampling times were longer in children with acute asthma (770.2 s, range: 532.2–900.1 s) compared to stable asthma (690.6 s, range: 477.5–900.1 s; p = 0.01). The ReCIVA successfully detected operational faults, in 21 samples. A leak, caused by a poor fit of the face mask seal was the most common (15); the others were USB communication-faults (5); and, a single instance of a file-creation error. Paediatric breath-profiles were reliably monitored, however synchronisation of sampling to breathing-phases was sometimes lost, causing some breaths not to be sampled, and some to be sampled continuously. This occurred in 60 (66.7%) of the samples and was a source of variability. Importantly, multi-variate modelling of untargeted VOC analysis indicated the absence of significant batch effects for eight operational variables. The ReCIVA appears suitable for paediatric breath-sampling. Post-processing of breath-sample meta-data is recommended to assess the quality of sample-acquisition. Further, future studies should explore the effect of pump-synchronisation faults on recovered VOC profiles, and mask sizes to fit all ages will reduce the potential for leaks and importantly, provide higher levels of comfort to children with asthma.


  • Open Access

    The Impact of a Graded Maximal Exercise Protocol on Exhaled Volatile Organic Compounds: A Pilot Study

    by Liam M. Heaney, Shuo Kang, Matthew A. Turner, Martin R. Lindley, C. L. Paul Thomas

    Exhaled volatile organic compounds (VOCs) are of interest due to their minimally invasive sampling procedure. Previous studies have investigated the impact of exercise, with evidence suggesting that breath VOCs reflect exercise-induced metabolic activity. However, these studies have yet to investigate the impact of maximal exercise to exhaustion on breath VOCs, which was the main aim of this study. Two-litre breath samples were collected onto thermal desorption tubes using a portable breath collection unit. Samples were collected pre-exercise, and at 10 and 60 min following a maximal exercise test (VO2MAX). Breath VOCs were analysed by thermal desorption-gas chromatography-mass spectrometry using a non-targeted approach. Data showed a tendency for reduced isoprene in samples at 10 min post-exercise, with a return to baseline by 60 min. However, inter-individual variation meant differences between baseline and 10 min could not be confirmed, although the 10 and 60 min timepoints were different (p = 0.041). In addition, baseline samples showed a tendency for both acetone and isoprene to be reduced in those with higher absolute VO2MAX scores (mL(O2)/min), although with restricted statistical power. Baseline samples could not differentiate between relative VO2MAX scores (mL(O2)/kg/min). In conclusion, these data support that isoprene levels are dynamic in response to exercise.


  • Open Access

    The variability of volatile organic compounds in the indoor air of clinical environments

    by Dahlia Salman, Wadah Ibrahim, Amisha Kanabar, Abigail Joyce, Bo Zhao, Amisha Singapuri, Michael Wilde, Rebecca L Cordell, Teresa McNally, Dorota Ruszkiewicz, et al.

    The development of clinical breath-analysis is confounded by the variability of background volatile organic compounds (VOCs). Reliable interpretation of clinical breath-analysis at individual, and cohort levels requires characterisation of clinical-VOC levels and exposures. Active-sampling with thermal-desorption/gas chromatography-mass spectrometry recorded and evaluated VOC concentrations in 245 samples of indoor air from three sites in a large National Health Service (NHS) provider trust in the UK over 27 months. Data deconvolution, alignment and clustering isolated 7344 features attributable to VOC and described the variability (composition and concentration) of respirable clinical VOC. 328 VOC were observed in more than 5% of the samples and 68 VOC appeared in more than 30% of samples. Common VOC were associated with exogenous and endogenous sources and 17 VOC were identified as seasonal differentiators. The presence of metabolites from the anaesthetic sevoflurane, and putative-disease biomarkers in room air, indicated that exhaled VOC were a source of background-pollution in clinical breath-testing activity. With the exception of solvents, and waxes associated with personal protective equipment (PPE), exhaled VOC concentrations above 3 µg m−3 are unlikely to arise from room air contamination, and in the absence of extensive survey-data, this level could be applied as a threshold for inclusion in studies, removing a potential environmental confounding-factor in developing breath-based diagnostics.


  • IABR Symposium 2021 meeting report: breath standardization, sampling, and testing in a time of COVID-19

    by Alexander J Schmidt, Dahlia Salman, Joachim Pleil, C L Paul Thomas, Cristina E Davis

    Due to COVID-19 travel disruptions, the International Association of Breath Research hosted the planned 2021 Breath Summit virtually as a symposium with oral and poster presentations. The event was comprised of a week-long social media asynchronous online event for sharing research abstracts, posters and discussions. Subsequently, there were two days of real-time webinar platform interactions each featuring three technical presentations, open forum questions, answers, and commentary. The symposium was well attended and well received. It allowed the breath community to share new research and to reconnect with colleagues and friends. This report presents an overview of the topics presented and various salient discussion points.


  • Open Access

    THE VARIABILITY OF VOLATILE ORGANIC COMPOUNDS IN CLINICAL ENVIRONMENTS

    by Dahlia Salman, Wadah Ibrahim, Amisha Kanabar, Bo Zhao, Amisha Singapuri, Michael Wilde, Rebecca Cordell, Teresa McNally, Dorota Ruszkiewicz, Andria Hadjithekli, et al.

    The development of clinical breath-analysis is confounded by the variability of background volatile organic compounds (VOC). Interpretation of clinical breath-data at individual, and cohort levels requires characterisation of clinical-VOC levels and exposures. Active-sampling with thermal-desorption/gas chromatography-mass spectrometry recorded and evaluated VOC concentrations in 245 samples of indoor air from three sites in a large NHS provider trust in the UK over 27 months. 7344 clinical VOC were isolated and 328 VOC and 68 were observed in more than 5% and 30% of samples respectively; associated with exogenous and endogenous sources. 17 VOC were seasonal differentiators. Metabolites from the anaesthetic sevoflurane, and putative-disease biomarkers in room air indicated that exhaled VOC were a source of background-pollution in clinical breath-tests. Apart from solvents, and PPE-waxes, exhaled VOC concentrations above 3 µgm-3 are unlikely to arise from room air contamination. This level could be applied as a threshold for inclusion in studies.